Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus for Nosebleeds in HHT
NCT05269849Phase 2Completed
- Sponsor
- Unity Health Toronto
- Start
- Mar 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sirolimus in hereditary hemorrhagic telangiectasia (HHT), sponsored by Unity Health Toronto. Primary endpoints: Electrolytes at 9 months, Hemoglobin at 9 months and 8 more. Started Mar 2022; status: completed.
02
Drugs
sirolimus
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on NCT05269849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05269849.